查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086150

口服蛋白和胜肽市場：2026-2032年全球市場預測（按產品類型、配方、患者類型、應用、最終用戶和分銷管道分類）

Oral Proteins & Peptides Market by Product Type, Formulation, Patient Type, Application, End-User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，口服蛋白質和胜肽市場將成長至 186.6 億美元，複合年成長率為 13.29%。

主要市場統計數據
基準年 2025 77.8億美元
預計年份：2026年 88億美元
預測年份 2032 186.6億美元
複合年成長率 (%) 13.29%

口服蛋白質和胜肽類藥物市場正從長期存在的製劑難題轉變為策略性藥物成長領域。由於胃腸道酵素、黏液屏障和上皮緊密連接等因素限制了口服生物利用度，GLP-1受體促效劑、胰島素候選藥物、副甲狀腺素類似物、抑鈣素和生長抑素類似物等蛋白質和勝生長抑制素類療法歷來依賴注射生物有效性。

然而，商業性進展已證實了該領域的有效性。 2019年，美國FDA核准口服Semaglutide作為首個口服GLP-1受體促效劑；2020年，口服Octreotide膠囊核准用於肢端肥大症的維持治療。在這些突破性進展的背景下，旨在提高吸收率並維持胜肽穩定性的滲透增強劑、酵素抑制劑、腸溶包衣、奈米顆粒、黏膜黏附系統和裝置整合膠囊等領域的投資正在不斷增加。

口服胜肽遞送領域的變革性變化

最顯著的變化是從概念驗證（PoC）口服給藥轉向差異化的產品生命週期策略。製藥開發商正利用口服胜肽類藥物計畫來提高患者依從性、拓展治療選擇、減輕注射負擔，並增強其在慢性病領域的競爭力，因為便利性直接影響治療的連續性。

人工智慧（AI）的累積影響

人工智慧透過改進胜肽設計、輔料選擇、穩定性預測和製劑篩檢，加速了口服蛋白質和胜肽的開發。機器學習模型可以評估分子量、電荷、疏水性、蛋白水解敏感性、滲透性和釋放動力學之間的關係，從而減少篩選有前景的候選藥物所需的實驗室迭代次數。

全球市場的關鍵區域洞察

北美憑藉其集中的生物技術能力、先進的臨床試驗基礎設施、與支付方的緊密合作以及FDA在批准口服肽類藥物方面的豐富經驗，繼續保持關鍵區域的地位。美國糖尿病和肥胖症的高發生率支撐了市場需求，而加拿大則憑藉其公共資助的研究網路和日益成熟的製藥環境做出貢獻。

針對特定群體的關鍵洞察，以進行策略市場優先排序

在醫療保健覆蓋範圍擴大以及本地製造商配方、包裝和分銷能力提升的推動下，東南亞國協在口服胜肽市場擴張中正發揮著越來越重要的作用。新加坡和馬來西亞擁有先進的臨床和監管框架，而印尼、泰國、越南和菲律賓則擁有龐大的糖尿病和心血管代謝疾病患者群體，因此具有顯著優勢。

各國對口服蛋白質和胜肽的重點見解

美國是最具影響力的市場，這得益於其FDA的先例、專科藥物的高使用率以及龐大的肥胖和糖尿病患者群體。加拿大提供穩定的市場進入管道和研究合作機會，而墨西哥和巴西隨著私人醫療保健、專科處方和專科藥房管道的擴張，在拉丁美洲展現出巨大的需求潛力。

為行業領導者提供的實用建議

產業領導者應優先考慮那些可透過口服給藥展現出可衡量的臨床和商業性價值的候選藥物，包括用於治療需要長期用藥的慢性疾病的藥物。研發項目不僅應證明其生物利用度，還應證明其具有持續療效、良好的飲食耐受性、胃腸道耐受性，以及與注射劑相比，患者對其的明顯偏好。

調查方法

本執行摘要採用結構化的二手調查方法編寫，符合既定的市場情報標準。資訊來源包括法規核准記錄、公共機構出版刊物、同行評審文獻、臨床試驗註冊資訊、專利趨勢以及國際糖尿病聯盟（IDF）和世界衛生組織（WHO）等權威流行病學資訊來源。

結論

口服蛋白質和胜肽類藥物有望透過結合胜肽類藥物的高效性和口服給藥的便利性，徹底改變生物製藥療法。推動這一市場發展的因素包括：法規核准的順利推進、代謝性疾病治療需求的不斷成長以及藥物科學的快速發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 口服蛋白質與胜肽市場：依產品類型分類

  • 胰島素衍生蛋白
    • 含胰島素的製劑
    • 長效胰島素類似物
    • 速效胰島素類似物
    • 重組人類胰島素
  • 胜肽類藥物
    • 以抑鈣素的療法
    • Glucagon-Like Peptide-1受體促效劑
    • 血管加壓素類似物

第8章 口服蛋白質與胜肽市場：依製劑類型分類

  • 膠囊製劑
  • 液體
  • 粉末製劑
  • 片劑配方

第9章 口服蛋白質與胜肽市場：依患者類型分類

  • 兒童
  • 成人
  • 老年人

第10章 口服蛋白質與胜肽市場：依應用分類

  • 癌症治療
  • 心血管疾病
  • 糖尿病管理
  • 內分泌疾病

第11章 口服蛋白質與胜肽市場：依最終用戶分類

  • 居家醫療
  • 醫院和診所
  • 研究所
  • 專科診所

第12章 口服蛋白質與胜肽市場：依分銷管道分類

  • 離線
  • 線上

第13章 口服蛋白質與胜肽市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 口服蛋白質與胜肽市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 口服蛋白質與胜肽市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Amryt Pharma plc
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Entera Bio Ltd. by DNA Biomedical Solutions
  • F. Hoffmann-La Roche AG
  • Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • PeptiDream Inc.
  • Pfizer, Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi SA
  • Tarsa Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S
Product Code: MRR-036C5CF3B4AA

The Oral Proteins & Peptides Market is projected to grow by USD 18.66 billion at a CAGR of 13.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.78 billion
Estimated Year [2026] USD 8.80 billion
Forecast Year [2032] USD 18.66 billion
CAGR (%) 13.29%

The oral proteins and peptides market is moving from a long-standing formulation challenge into a strategic pharmaceutical growth arena. Protein and peptide therapeutics such as GLP-1 receptor agonists, insulin candidates, parathyroid hormone analogs, calcitonin, and somatostatin analogs have historically relied on injections because gastrointestinal enzymes, mucus barriers, and epithelial tight junctions restrict oral bioavailability.

Commercial progress has validated the category. The U.S. FDA approved oral semaglutide in 2019 as the first oral GLP-1 receptor agonist, and oral octreotide capsules were approved in 2020 for acromegaly maintenance therapy. These milestones support growing investment in permeation enhancers, enzyme inhibitors, enteric coatings, nanoparticles, mucoadhesive systems, and device-enabled capsules designed to improve absorption while preserving peptide stability.

Transformative Shifts in the Oral Peptide Delivery Landscape

The most important shift is the movement from proof-of-concept oral delivery toward differentiated product life-cycle strategies. Pharmaceutical developers are using oral peptide programs to improve patient adherence, extend therapeutic options, reduce injection burden, and compete in chronic diseases where convenience directly affects persistence.

Demand is being reinforced by the global burden of metabolic disease. The International Diabetes Federation estimated that 537 million adults were living with diabetes in 2021, while the World Health Organization reported that more than 1 billion people were living with obesity in 2022. These epidemiological realities make oral GLP-1 therapies, oral insulin approaches, and other peptide-based therapies high-priority targets for clinical development and commercialization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating oral protein and peptide development by improving peptide design, excipient selection, stability prediction, and formulation screening. Machine learning models can evaluate relationships among molecular weight, charge, hydrophobicity, proteolytic susceptibility, permeability, and release kinetics, reducing the number of laboratory iterations required to identify promising candidates.

AI is also influencing clinical and commercial execution. Predictive analytics support patient stratification, dose optimization, adherence modeling, pharmacovigilance signal detection, and manufacturing process control. As regulatory agencies increasingly accept model-informed drug development when supported by robust evidence, AI-enabled workflows are becoming a competitive advantage rather than a peripheral research tool.

Key Regional Insights Across Global Markets

North America remains a leading region because of its concentration of biotechnology capabilities, advanced clinical trial infrastructure, strong payer engagement, and FDA experience with oral peptide approvals. The United States anchors demand through high diabetes and obesity prevalence, while Canada contributes through publicly supported research networks and an increasingly sophisticated specialty pharmaceutical environment.

Europe benefits from established regulatory pathways through the European Medicines Agency, strong biologics manufacturing capabilities, and active peptide research across Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is gaining momentum as China, India, Japan, South Korea, and Australia expand clinical development capacity, contract manufacturing, and demand for chronic disease therapies. Latin America, led by Brazil and Mexico, shows rising access potential as metabolic disorders increase and private specialty channels develop, while the Middle East is shaped by high diabetes burden and healthcare modernization across Gulf health systems. Africa remains earlier in adoption but is increasingly relevant as urbanization, noncommunicable disease strategies, and medicine access initiatives expand across major economies.

Key Group Insights for Strategic Market Prioritization

ASEAN countries are becoming important for oral peptide market expansion as healthcare coverage improves and regional manufacturers strengthen formulation, packaging, and distribution capabilities. Singapore and Malaysia offer clinical and regulatory sophistication, while Indonesia, Thailand, Vietnam, and the Philippines provide sizable patient populations for diabetes and cardiometabolic therapies.

The GCC is increasingly relevant due to national diabetes management programs, specialty care investment, and healthcare transformation initiatives across Gulf economies. The European Union supports harmonized regulatory review, pharmacovigilance, and high-quality manufacturing standards that are important for complex oral biologics. BRICS countries offer scale, domestic manufacturing priorities, and rising demand for chronic disease treatment, particularly in China, India, and Brazil. G7 markets continue to lead premium innovation, clinical evidence generation, and reimbursement discussions, while NATO countries overlap heavily with advanced North American and European markets, supporting resilient supply chains, stringent quality expectations, and coordinated regulatory standards.

Key Country Insights for Oral Proteins and Peptides

The United States is the most influential country market due to FDA precedent, high specialty drug utilization, and a large population affected by obesity and diabetes. Canada offers stable market access pathways and research collaborations, while Mexico and Brazil provide important Latin American demand opportunities as private healthcare, specialist prescribing, and specialty pharmacy channels expand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine clinical research depth with advanced reimbursement systems, while Russia remains a differentiated market shaped by localization requirements, regulatory complexity, and access constraints. China and India are central to future scale because of large patient populations, active domestic pharmaceutical investment, expanding clinical trial activity, and policy focus on local production. Japan and South Korea contribute advanced drug delivery research, strong quality systems, and high adoption of innovative therapies, while Australia serves as a credible clinical development and early market access environment supported by recognized regulatory standards and research infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize candidates where oral delivery provides measurable clinical and commercial value, including chronic diseases requiring long-term adherence. Programs should demonstrate not only bioavailability but also durable efficacy, acceptable food-effect management, gastrointestinal tolerability, and clear patient preference versus injectable alternatives.

Organizations should invest in platform technologies, AI-enabled formulation screening, scalable manufacturing, and early regulatory engagement. Commercial teams should prepare evidence packages for payers that quantify adherence, persistence, total cost of care, and quality-of-life benefits. Partnerships with contract development and manufacturing organizations, academic laboratories, and digital adherence providers can reduce development risk and accelerate launch readiness.

Research Methodology

This executive summary is developed using a structured secondary research methodology aligned with established market intelligence standards. Inputs include regulatory approval records, public agency publications, peer-reviewed literature, clinical trial registries, patent activity, and recognized epidemiological sources such as the International Diabetes Federation and the World Health Organization.

The analysis triangulates technology trends, therapeutic demand, regional healthcare infrastructure, regulatory maturity, and commercialization dynamics. Insights are validated through consistency checks across multiple sources and are presented without unsupported market sizing, market share claims, or speculative forecasting.

Conclusion

Oral proteins and peptides are positioned to reshape biologic therapy by combining the potency of peptide drugs with the convenience of oral administration. The market is supported by proven regulatory milestones, expanding metabolic disease demand, and rapid advances in formulation science.

The strongest performers will be organizations that integrate drug delivery innovation, AI-driven development, clinical differentiation, scalable manufacturing, and payer-relevant outcomes. As oral peptide platforms mature, they can improve adherence, expand access, and create new competitive benchmarks across chronic and specialty care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oral Proteins & Peptides Market, by Product Type

  • 7.1. Insulin-Based Proteins
    • 7.1.1. Combination Insulin Products
    • 7.1.2. Long-Acting Insulin Analogues
    • 7.1.3. Rapid-Acting Insulin Analogues
    • 7.1.4. Recombinant Human Insulin
  • 7.2. Peptide Therapeutics
    • 7.2.1. Calcitonin-Based Therapies
    • 7.2.2. Glucagon-Like Peptide-1 Receptor Agonists
    • 7.2.3. Vasopressin Analogs

8. Oral Proteins & Peptides Market, by Formulation

  • 8.1. Capsule Formulations
  • 8.2. Liquid Formulations
  • 8.3. Powder Formulations
  • 8.4. Tablet Formulations

9. Oral Proteins & Peptides Market, by Patient Type

  • 9.1. Pediatric
  • 9.2. Adult
  • 9.3. Geriatric

10. Oral Proteins & Peptides Market, by Application

  • 10.1. Cancer Treatment
  • 10.2. Cardiovascular Diseases
  • 10.3. Diabetes Management
  • 10.4. Hormonal Disorders

11. Oral Proteins & Peptides Market, by End-User

  • 11.1. Home Care Settings
  • 11.2. Hospitals & Clinics
  • 11.3. Research Laboratories
  • 11.4. Specialty Clinics

12. Oral Proteins & Peptides Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Oral Proteins & Peptides Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Oral Proteins & Peptides Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Proteins & Peptides Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. Amryt Pharma plc
  • 17.4. Astellas Pharma Inc.
  • 17.5. AstraZeneca PLC
  • 17.6. Biocon Limited
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Catalent, Inc.
  • 17.9. Entera Bio Ltd. by DNA Biomedical Solutions
  • 17.10. F. Hoffmann-La Roche AG
  • 17.11. Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • 17.12. Johnson & Johnson Services, Inc.
  • 17.13. Merck KGaA
  • 17.14. Novartis AG
  • 17.15. Novo Nordisk A/S
  • 17.16. Oramed Pharmaceuticals Inc.
  • 17.17. PeptiDream Inc.
  • 17.18. Pfizer, Inc.
  • 17.19. Protagonist Therapeutics, Inc.
  • 17.20. Proxima Concepts Limited
  • 17.21. Rani Therapeutics, LLC
  • 17.22. Sanofi S.A.
  • 17.23. Tarsa Therapeutics, Inc.
  • 17.24. Teva Pharmaceutical Industries Ltd.
  • 17.25. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSULIN-BASED PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSULIN-BASED PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSULIN-BASED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMBINATION INSULIN PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMBINATION INSULIN PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMBINATION INSULIN PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LONG-ACTING INSULIN ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LONG-ACTING INSULIN ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LONG-ACTING INSULIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RAPID-ACTING INSULIN ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RAPID-ACTING INSULIN ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RAPID-ACTING INSULIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT HUMAN INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT HUMAN INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CALCITONIN-BASED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CALCITONIN-BASED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CALCITONIN-BASED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASOPRESSIN ANALOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VASOPRESSIN ANALOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASOPRESSIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAPSULE FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAPSULE FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAPSULE FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TABLET FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TABLET FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TABLET FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HORMONAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HORMONAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HORMONAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 318. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 328. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)